A case of HER-2-positive recurrent breast cancer showing a clinically complete response to trastuzumab-containing chemotherapy after primary treatment of triple-negative breast cancer

World Journal of Surgical Oncology

Volumn 9, Issue , 2011, Pages

  Shigematsu, Hideo ^a   Kadoya, Takayuki ^a   Kobayashi, Yoshie ^a   Kajitani, Keiko ^a   Sasada, Tatsunari ^a   Emi, Akiko ^a   Masumoto, Norio ^a   Haruta, Rumi ^a   Kataoka, Tsuyoshi ^a   Oda, Miyo ^a   Arihiro, Kouji ^a   Okada, Morihito ^a  

^a HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

discordance; HER 2; Recurrent breast cancer; trastuzumab

Indexed keywords

CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; PACLITAXEL; PROGESTERONE RECEPTOR; TRASTUZUMAB; ANTINEOPLASTIC AGENT; HER2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CLINICAL ASSESSMENT; DRUG DOSE REDUCTION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; RECURRENT CANCER; TREATMENT RESPONSE; BREAST TUMOR; GENETICS; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; REMISSION; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 80355125175     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-9-146     Document Type: Article

References (16)

1. Curigliano G, Bagnardi V, Viale G, Fumagalli L, Rotmensz N, Aurilio G, Locatelli M, Pruneri G, Giudici S, Bellomi M, et al. Should liver metastases of breast cancer be biopsied to improve treatment choice?. Ann Oncol 2011,
2. Idirisinghe PK, Thike AA, Cheok PY, Tse GM, Lui PC, Fook-Chong S, Wong NS, Tan PH. Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance. Am J Clin Pathol 2010, 133:416-429. 10.1309/AJCPJ57FLLJRXKPV, 20154280.
3. Guarneri V, Giovannelli S, Ficarra G, Bettelli S, Maiorana A, Piacentini F, Barbieri E, Dieci MV, D'Amico R, Jovic G, Conte P. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. Oncologist 2008, 13:838-844. 10.1634/theoncologist.2008-0048, 18650259.
4. Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, Albarracin C, Meric-Bernstam F, Woodward W, Theriault RL, et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 2009, 20:1953-1958. 10.1093/annonc/mdp263, 2791352, 19596702.
5. Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, Dranitsaris G, Clemons MJ. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?. Ann Oncol 2009, 20:1499-1504. 10.1093/annonc/mdp028, 2731014, 19299408.
6. Xiao C, Gong Y, Han EY, Gonzalez-Angulo AM, Sneige N. Stability of HER2-positive status in breast carcinoma: a comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment. Ann Oncol 2011,
7. Gong Y, Booser DJ, Sneige N. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 2005, 103:1763-1769. 10.1002/cncr.20987, 15786420.
8. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
9. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009, 20:1319-1329. 10.1093/annonc/mdp322, 2720818, 19535820.
10. Shigematsu H, Kawaguchi H, Nakamura Y, Tanaka K, Shiotani S, Koga C, Nishimura S, Taguchi K, Nishiyama K, Ohno S. Significant survival improvement of patients with recurrent breast cancer in the periods 2001-2008 vs. 1992-2000. BMC Cancer 2011, 11:118. 10.1186/1471-2407-11-118, 3080832, 21453503.
11. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792. 10.1056/NEJM200103153441101, 11248153.
12. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005, 23:4265-4274. 10.1200/JCO.2005.04.173, 15911866.
13. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 2010, 28:92-98. 10.1200/JCO.2008.19.9844, 2799236, 19933921.
14. Varadarajan R, Edge SB, Yu J, Watroba N, Janarthanan BR. Prognosis of occult breast carcinoma presenting as isolated axillary nodal metastasis. Oncology 2006, 71:456-459. 10.1159/000107111, 17690561.
15. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009, 27:1323-1333. 10.1200/JCO.2007.14.8197, 19204209.
16. Bozzetti C, Nizzoli R, Guazzi A, Flora M, Bassano C, Crafa P, Naldi N, Cascinu S. HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer. Ann Oncol 2002, 13:1398-1403. 10.1093/annonc/mdf217, 12196365.